Zydus Lifesciences has taken a significant step toward expanding its global footprint by signing an agreement to acquire a controlling stake in Amplitude Surgical, a France-based company.
Zydus Lifesciences (“Zydus”) has announced the signing of a share purchase agreement to acquire a 75.4 per cent stake in Amplitude Surgical SA (“Amplitude”) for €6.25 per share from PAI Partners, Olivier Jallabert and other managers of Amplitude. This follows the completion of the mandatory information and consultation process with the works council of Amplitude SAS, as reported by Zydus Lifesciences.
Additionally, Zydus entered into two separate share purchase agreements on March 11, 2025, with minority shareholders. Together, these transactions—referred to as the “Block Acquisition” will give Zydus control of 85.6 per cent of Amplitude’s share capital. The completion of the Block Acquisition remains subject to standard closing conditions, including approval from the French Minister of Economy under regulations governing foreign investments, the reinvestment by Amplitude CEO Olivier Jallabert into the company, and the absence of any material adverse events, as outlined in Zydus Lifesciences’ report.
Upon successful completion of these conditions, which is expected by Q3 2025, Zydus will move forward with a mandatory simplified tender offer to the Autorité des Marchés Financiers (“AMF”). As of April 17, 2025, commitments to tender an additional 4.7 per cent of Amplitude’s share capital have been secured from minority shareholders. This will enable Zydus to surpass 90 per cent ownership of Amplitude’s capital and voting rights, facilitating a squeeze-out procedure thereafter.
This strategic acquisition represents a significant milestone in Zydus Lifesciences’ global expansion plans, strengthening its position in the orthopaedic surgical solutions market.
